Dasatinib in Patients With Chronic Myeloid Leukemia in Chronic Phase

Chronic Myeloid Leukemia Clinical Trial

— DASAPOST  

Official title:

Multicenter, Open-label, Non-randomized Phase II Trial of Dasatinib in Patients With Chronic Myeloid Leukemia in Chronic Phase (CP-CML) Who Meet Criteria for Late Suboptimal Response After Prior Imatinib Treatment

Clinical Trial Details — Status: Unknown status

Administrative data

• NCT number: NCT01802450
• Other study ID #: DASAPOST
• Status: Unknown status
• Phase: Phase 2
• First received: February 27, 2013
• Last updated: September 16, 2015
• Start date: March 2013
• Est. completion date: December 2016

Study information

• Verified date: September 2015
• Source: PETHEMA Foundation
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

Trial try to assess the efficacy of dasatinib in terms of major molecular response rate at 6 months in patients with CP-CML who have achieved complete cytogenetic response without major molecular response after at least 18 months on Imatinib 400/600.

Description:

This is a single-arm, open-label, phase II trial for patients in complete cytogenetic response that have not achieved major molecular response or have lost a prior major molecular response, after at least 18 months of treatment with imatinib.

All enrolled patients will receive dasatinib 100 mg once daily orally for 1 year until progression, loss of cytogenetic response, transformation to advanced phases, unacceptable toxicity (clinical adverse event, lab abnormality or concurrent disease), pregnancy if a female or withdrawal of consent, whichever happens first. Patients will undergo BCR-ABL assessments at study entry and every 3 months (central lab) and immunophenotyping and studies for clonal lymphocytosis at study entry, at 3 and 6 months.

Cytogenetic assessment will be done only if loss of response/progression/clonal evolution are suspected.

Subjects will be evaluated for the efficacy and safety of dasatinib (Sprycel). Lymphocytosis data will be collected for all patients and separate description for efficacy and safety parameters will be done in patients with and without lymphocytosis.

Recruitment information / eligibility

• Status: Unknown status
• Enrollment: 18
• Est. completion date: December 2016
• Est. primary completion date: June 2015
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• Adult patients >or = 18 years

• Diagnostic of Ph+ Chronic Myeloid Leukemia in first chronic phase

• Treated with Imatinib 400 mg per day or 600 mg per day for at least 18 months. A wash out period of at least 7 days for imatinib is required prior to dasatinib administration

• Patients meet criteria of late suboptimal response (complete cytogenetic response with no major molecular response) or have lost major molecular response

• Ability to understand and voluntarily sign the informed consent for

• Women of childbearing potential (WOCBP) must be using an adequate method of contraception to avoid pregnancy and have a negative pregnancy test, a maximum of 72 hours prior to study drug start.

Sexually active men must also use effective contraceptive methods during the treatment.

• Women must not be breastfeeding

Exclusion Criteria:

• Patients treated with Imatinib at a dose different of 400/600 mg per day

• Patients treated with other TKI than imatinib

• Loss of cytogenetic response at study entry

• ECOG = 3

• Inadequate bone marrow reserve: ANC <1.5 x 109/L and/or Platelet count < 100 x 109/L

• Inadequate hepatic function (Alanine aminotransferase (ALT) and/or aspartate aminotransferase (AST)> 2.5 X institutional upper limit of normal (IULN). Total bilirubin > 1.5 X IULN (unless Gilbert syndrome has been diagnosed)

• Inadequate renal function (serum Cr >3 UNL or ClCr <45 ml/min)

• Patients receiving concurrent treatment with other experimental drugs or anti-cancer therapy

• Patients with uncontrolled concurrent disease:

Known pleural effusion at baseline Clinically-significant gastrointestinal disease or surgery that would compromise absorption of study drug (eg, uncontrolled nausea or malabsorption syndrome) Clinically-significant known coagulation or platelet function disorder (not related to thrombocytopenia), eg, von Willebrand's disease Other active malignancy requiring concurrent intervention

Uncontrolled or significant cardiovascular disease, including any of the following:

Myocardial infarction within 6 months of enrolment date Uncontrolled angina or congestive heart failure within 3 months of enrolment date Left ventricular ejection fraction (LVEF) < 40% Significant cardiac conduction abnormality, including history of clinically-significant ventricular arrhythmia (such as ventricular tachycardia, ventricular fibrillation, or Torsades de Pointes), history of third degree heart block or diagnosed congenital long QT syndrome, and/or prolonged QTc/f interval > 450 msec on baseline ECG.

• Patients with active or uncontrolled infections or with serious illnesses or medical conditions that would not permit the patient to be managed according to the protocol.

• Patients unable or unwilling to give written, informed consent prior to study participation.

Related Conditions & MeSH terms

• Chronic Myeloid Leukemia
• Leukemia
• Leukemia, Myelogenous, Chronic, BCR-ABL Positive
• Leukemia, Myeloid

Intervention

Drug:
• Dasatinib

Locations

Country	Name	City	State
Spain	Hospital Germans Trias i Pujol	Badalona	Barcelona
Spain	Institut Catalá d'Oncologia L'Hospitallet	Barcelona
Spain	Hospital de León	León
Spain	Hospital San Pedro de La Rioja	Logroño	La Rioja
Spain	Hospital 12 de Octubre	Madrid
Spain	Hospital Universitario de la Princesa	Madrid
Spain	Hospital Universitario La Paz	Madrid
Spain	Hospital Universitario Ramón y Cajal	Madrid
Spain	Hospital Universitario Central de Asturias	Oviedo	Asturias
Spain	Hospital Universitario de Salamanca	Salamanca
Spain	Complejo Hospitalario Universitario de Santiago	Santiago de Compostela	La Coruña
Spain	Hospital Virgen del Rocío	Sevilla
Spain	Complejo Hospitalario de Toledo - Hospital Virgen de la Salud	Toledo	Castilla La Mancha
Spain	Hospital POVISA	Vigo	Pontevedra
Spain	Hospital Txagorritxu	Vitoria	Alava

Sponsors (3)

Lead Sponsor	Collaborator
PETHEMA Foundation	Bristol-Myers Squibb, Dynamic Solutions

Country where clinical trial is conducted

Spain, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Asses the efficacy	To assess the efficacy of dasatinib in terms of major molecular response rate at 6 months in patients with CP-CML who have achieved complete cytogenetic response without major molecular response after at least 18 months on Imatinib 400/600	1 year
Secondary	Asses the efficacy	To assess the efficacy of dasatinib in terms of depth and kinetics of molecular response	1 year
Secondary	Assess the relationship of dasatinib with the appearance of large granular lymphocytes	To assess the relationship of dasatinib with the appearance of large granular lymphocytes and assess the relationship of LGL with efficacy and toxicity	6 months

External Links

•   Bristol Myers Squibb
•   Dynamic Solutions CRO